Vidalta is licensed for the treatment of hyperthyroidism and hyperthyroidism clinical signs in cats. Vidalta tablets are prolonged release allowing for once daily dosing.  Vidalta tablets contain the active carbimazole which is a metabolic prodrug that is rapidly and almost entirely converted to methimazole in vivo. Methimazole concentrates in the thyroid glands where it blocks the activity of the enzyme thyroid peroxidise and thereby regulates the production of thyroid hormones in a dose dependent manner.

The absorption of methimazole when administered as Vidalta prolonged release tablets is delayed compared to conventional release tablets. The concentration/time profile is flatter ensuring there is no pronounced methimazole peaks.

Legal category: POM-V

Vidalta 10mg tablets contain 10mg carbimazole as active ingredient

Colouring agent: Red ferric oxide (E172): 0.25 mg

Vidalta 15mg tablets contain 15mg carbimazole as active ingredient.

Colouring agent: Red ferric oxide (E172): 0.75mg